Investors Presentation
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Earkart Ltd, a hearing healthcare company listed on BSE SME, shared its H1FY26 investor presentation showing a revenue dip of 5.37% YoY to Rs 2,228.57 lakhs, with EBITDA falling 37% to Rs 315.79 lakhs and PAT declining 44% to Rs 185.33 lakhs. Management attributed the slowdown to deferred government orders (69% of revenue) now expected to execute in November-December 2025. The company highlighted strong 25% growth in its private market segment, a newly granted 20-year patent for its 'Smart Sound Treatment and Diagnosis System,' and international expansion plans into the US and Australia following positive response at a major ENT conference.
Near-term margin pressure is visible with EBITDA margins contracting from 21.3% to 14.2%, but management guides for recovery in H2FY26 driven by pent-up government orders and an 18% revenue CAGR outlook. Shareholders should watch November-December order execution and progress on the target of scaling from 49 to 510 SIS clinics by 2027 as key catalysts.